Lamis Alharby

Dr. Lamis Alharby

Moorfields Eye Hospital
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GGGlobal Retinoblastoma Study Group
Global Retinoblastoma Study Group
IFIdo Didi Fabian
Ido Didi Fabian
EAElhassan Abdallah
Elhassan Abdallah
SAShehu U. Abdullahi
Shehu U. Abdullahi
RARula A. Abdulqader
Rula A. Abdulqader
RBRichard Bowman
Richard Bowman
Retinoblastoma, the most common eye cancer of childhood, is fatal if left untreated. Prognosis of patients with retinoblastoma in high-income countries (HICs) has improved over the past 50 years, now reaching a near 100% disease-free survival rate.1-3 This is attributed to several factors, including (1) creation of specialized referral centers, (2) decoding of the genetic basis of the disease, (3) formation of screening programs, and (4) the introduction of chemotherapy.4 In HICs, retinoblastoma is a curable disease, and attention has now shifted to eye salvage5,6 and improvement of quality of life.7 In low- and middle-income countries (LMICs), where more than 80% of global retinoblastoma cases arise, the prognosis is poor, and it is assumed that this is because of delayed diagnosis and treatment.8-10 Publications from LMICs are scarce, and many countries do not report their retinoblastoma data.11 The stage of retinoblastoma at the time of diagnosis in low-income, middle-income, and high-income countries has not been surveyed globally. This information is important for policy and health care planning at national and international levels.

21 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KRKelsey Roelofs
Kelsey Roelofs
RORoderick O’day
Roderick O’day
LALamis Alharby
Lamis Alharby
AAAmit K. Arora
Amit K. Arora
VCVictoria Cohen
Victoria Cohen
Bertil E. DamatoBertil E. Damato
Bertil E. Damato
Purpose: To evaluate the MOLES system for identifying malignancy in melanocytic choroidal tumors in patients treated for choroidal melanoma. Methods: Records of 615 patients treated for choroidal melanoma between January 2017 and December 2019 were reviewed. Patients were excluded if iris and/or ciliary body involvement (106 patients), inadequate fundus photography (26 patients), no images available for review (21 patients) and/or treatment was not primary (11 patients). Demographic data and AJCC TNM Stage were collected. Color fundus and autofluorescence photographs (FAF), optical coherence tomography (OCT) and B-scan ultrasounds were prospectively reviewed. MOLES scores were assigned according to five criteria: mushroom shape, orange pigment, large size, enlarging tumor and subretinal fluid. Results: A total of 451 patients (mean age, 63.9 ± 13.9 years) were included. At treatment, mean largest basal tumor diameter (LBD) and thickness were 10.3 ± 2.8 mm (range, 3.0–23.0) and 4.3 mm (range, 1.0–17.0). All but one (0.2%) had MOLES scores of ≥3. Eighty-two patients were treated after surveillance lasting a mean of 1.5 years. Initially, most (63/82; 76.8%) had a MOLES score ≥ 3. Importantly, none of the 451 tumors had a score of <2, and as such, the MOLES protocol would have indicated referral to an ocular oncologist for 100% of patients. Conclusion: The MOLES scoring system is a sensitive (99.8%) tool for indicating malignancy in melanocytic choroidal tumors (MOLES ≥ 3). If the examining practitioner can recognize the five features suggestive of malignancy, MOLES is a safe tool to optimize referral of melanocytic choroidal tumors for specialist care.

24 March 2017 in Eye
Verified
Journal Article
Closed access
IFIdo Didi Fabian
Ido Didi Fabian
ASA W Stacey
A W Stacey
VPV Papastefanou
V Papastefanou
LALamis Alharby
Lamis Alharby
AAA K Arora
A K Arora
VCVictoria Cohen
Victoria Cohen

19 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SKSWATHI KALIKI
SWATHI KALIKI
XJXunda Ji
Xunda Ji
YZYihua Zou
Yihua Zou
RRRiffat Rashid
Riffat Rashid
SSSadia Sultana
Sadia Sultana
IFIdo Didi Fabian
Ido Didi Fabian
Background: The relationship between lag time and outcomes in retinoblastoma (RB) is unclear. In this study, we aimed to study the effect of lag time between onset of symptoms and diagnosis of retinoblastoma (RB) in countries based on their national-income and analyse its effect on the outcomes. Methods: We performed a prospective study of 692 patients from 11 RB centres in 10 countries from 1 January 2019 to 31 December 2019. Results: The following factors were significantly different among different countries based on national-income level: age at diagnosis of RB (p = 0.001), distance from home to nearest primary healthcare centre (p = 0.03) and mean lag time between detection of first symptom to visit to RB treatment centre (p = 0.0007). After adjusting for country income, increased lag time between onset of symptoms and diagnosis of RB was associated with higher chances of an advanced tumour at presentation (p < 0.001), higher chances of high-risk histopathology features (p = 0.003), regional lymph node metastasis (p < 0.001), systemic metastasis (p < 0.001) and death (p < 0.001). Conclusions: There is a significant difference in the lag time between onset of signs and symptoms and referral to an RB treatment centre among countries based on national income resulting in significant differences in the presenting features and clinical outcomes.

1 April 2016 in Eye
Verified
Journal Article
Closed access
VPV P Papastefanou
V P Papastefanou
MPM Pefkianaki
M Pefkianaki
LALamis Alharby
Lamis Alharby
AAA K Arora
A K Arora
VCVictoria Cohen
Victoria Cohen
MSMandeep S. Sagoo
Mandeep S. Sagoo

15 March 2021 in Ocular Oncology and Pathology
Verified
Journal Article
Open access
PDF file
LALamis Alharby
Lamis Alharby
MSMandeep S. Sagoo
Mandeep S. Sagoo
RORoderick O’dAy
Roderick O’dAy
GHGordon Hay
Gordon Hay
AAAmit K. Arora
Amit K. Arora
Bertil E. DamatoBertil E. Damato
Bertil E. Damato
Objective: The aim of this study was to determine the sensitivity and specificity of the MOLES scoring system in differentiating choroidal melanomas from nevi according to Mushroom shape, Orange pigment, Large tumor size, Enlarging tumor, and Subretinal fluid (SRF). Methods: Color photographs, fundus-autofluorescence images, and optical coherence tomography of 222 melanocytic choroidal tumors were reviewed. Each MOLES feature was retrospectively scored between 0 and 2 and tumors categorized as “common nevus,” “low-risk nevus,” “high-risk nevus,” and “probable melanoma” according to the total score. MOLES scores were compared with the experts’ diagnosis of melanoma. Results: The MOLES scoring system indicated melanoma in all 81 tumors diagnosed as such by ocular oncologists (100% sensitivity) and nevus in 135 of 141 tumors given this diagnosis by these experts (95.7% specificity). Of the 6 tumors with discordant diagnoses, 4 had basal diameters exceeding 6 mm, all with SRF and/or orange pigment, and 2 small tumors showed either significant SRF with traces of orange pigment, or vice versa. Conclusions: The MOLES system for diagnosing melanocytic choroidal tumors compares well with expert diagnosis but needs to be evaluated when deployed by ophthalmologists and community optometrists in a wide variety of working environments.